Company Description
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
The company’s commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease.
The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide.
It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jul 28, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 592 |
| CEO | Michael Castagna |
Contact Details
Address: 1 Casper Street Danbury, Connecticut 06810 United States | |
| Phone | 818 661 5000 |
| Website | mannkindcorp.com |
Stock Details
| Ticker Symbol | MNKD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899460 |
| CUSIP Number | 56400P706 |
| ISIN Number | US56400P7069 |
| Employer ID | 13-3607736 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael E. Castagna Pharm.D. | Chief Executive Officer and Director |
| Christopher B. Prentiss M.B.A. | Chief Financial Officer |
| Dr. David B. Thomson J.D., Ph.D. | Executive Vice President, General Counsel and Secretary |
| Dr. Stuart A. Tross Ph.D. | Chief People and Workplace Officer |
| Dominic Marasco R.Ph. | President of Endocrine Business Unit |
| Sanjay Singh M.B.A. | Executive Vice President of Technical Operations |
| Dr. Ajay Ahuja M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Wassim Fares M.D., M.Sc. | Senior Vice President and Therapeutic Area Head of Respiratory and (interim) Cariorenal |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2026 | 144 | Filing |
| Sep 10, 2026 | 144 | Filing |
| Aug 21, 2026 | 8-K | Current Report |
| Aug 21, 2026 | 424B7 | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 7, 2026 | 144 | Filing |
| Aug 5, 2026 | 10-Q | Quarterly Report |
| Aug 5, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SCHEDULE 13G | Filing |
| Jul 24, 2026 | 8-K | Current Report |